Axsome Therapeutics, Inc.
AXSM Nasdaq
SEC CIK 1579428
Follow Axsome Therapeutics
Weekly email: filings, results
Revenue, last quarter
$259.7M
+51.9% vs same quarter last year
Net income
−$12.9M
+72.7% vs same quarter last year
EPS, diluted
−$0.25
+73.4% vs same quarter last year
Operating cash flow
−$9.5M
−1005.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $638.5M | −$183.2M |
| FY24 | $385.7M | −$287.2M |
| FY23 | $270.6M | −$239.2M |
| FY22 | $50M | −$187.1M |
| FY21 | - | −$130.4M |
| FY20 | - | −$102.9M |
| FY19 | - | −$68.3M |
| FY18 | - | −$31M |
| FY17 | - | −$28.9M |
| FY16 | - | −$27.2M |
| FY15 | - | −$12.2M |
| FY14 | - | −$6M |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −26.1% | −28.7% |
| FY24 | −72.7% | −74.5% |
| FY23 | −85.7% | −88.4% |
| FY22 | −359.3% | −374% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$93.9M |
| FY24 | −$128.7M |
| FY23 | −$145.7M |
| FY22 | −$117.2M |
| FY21 | −$108.5M |
| FY20 | −$78.5M |
| FY19 | −$46.4M |
| FY18 | −$30.1M |
| FY17 | −$26.5M |
| FY16 | −$21.4M |
| FY15 | −$7.5M |
| FY14 | - |
| FY13 | - |
- Axsome Therapeutics
- Healthcare median
Show the numbers
| Year | Axsome Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −28.7% | −30.6% |
| FY24 | −74.5% | −47% |
| FY23 | −88.4% | −58% |
| FY22 | −374% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |